Canaccord Genuity upgrades Cochlear stock to Buy on Nucleus Nexa potential
PositiveFinancial Markets

Canaccord Genuity has upgraded Cochlear's stock to a 'Buy' rating, citing the promising potential of its Nucleus Nexa product. This upgrade is significant as it reflects confidence in Cochlear's innovative technology and its ability to enhance hearing solutions, which could lead to increased market performance and investor interest.
— Curated by the World Pulse Now AI Editorial System